Results 41 to 50 of about 39,539 (240)
Background/Objectives: Rapid development of vaccines against SARS-CoV-2 was pivotal to controlling the COVID-19 pandemic. The emergency also provided a rare opportunity to test novel vaccine platforms such as mRNA in large clinical trials.
Puthupparampil V. Scaria +19 more
doaj +1 more source
Respiratory Organ‐on‐a‐Chip for Disease Modeling: From Architecture to Functional Integration
Respiratory organ‐on‐a‐chip (ROC) models capture key mechanical and cellular cues of the human respiratory system, enabling quantitative dissection of disease mechanisms. This review links ROC architectures to disease modeling, functional integration, and commercialization, and proposes a decision framework that aligns model complexity with mechanistic
Jinzhuo Hu +4 more
wiley +1 more source
Conjugate Vaccines and the Carriage of Haemophilus influenzae Type b
Pharyngeal carriage of Haemophilus influenzae type b (Hib) is important in the transmission of Hib organisms, the pathogenesis of Hib disease, and the development of immunity to the bacterium.
Marina L. Barbour, D. Phil
doaj +1 more source
Shellac‐Mediated Assembly of Nanoparticles for mRNA Delivery
A shellac‐mediated nanoparticle assembly strategy is presented, involving the complexation of mRNA and low‐molecular‐weight cationic molecules (e.g., polyethyleneimine, chitosan, lipids, and poly‐l‐lysine), followed by capping with shellac. This nanoparticle platform enables mRNA transfection following intravenous injection and facilitates gene editing
Meizhang Lu +7 more
wiley +1 more source
State of pneumococcal vaccine immunity
Like the other invasive encapsulated bacteria, Streptococcus pneumoniae is also covered with a polysaccharide structure. Infants and elderly are most vulnerable to the invasive and noninvasive diseases caused by S. pneumoniae. Although antibodies against
Mustafa Akkoyunlu
doaj +1 more source
Bacteria‐Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy
Bacteria‐responsive nanocarriers are designed to release antimicrobials only in the presence of infection‐specific cues. This selective activation ensures drug release precisely at the site of infection, avoiding premature or indiscriminate release, and enhancing efficacy.
Guillermo Landa +3 more
wiley +1 more source
The serogroup distribution of Neisseria meningitidis strains implicated in invasive disease varies geographically and temporally. Monovalent serogroup C conjugate vaccines have successfully reduced serogroup C disease in countries where they are used ...
Jacqueline Miller +2 more
doaj
Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects
Mesoporous silica nanoparticles offer unique properties like high surface area, tunable pores, and functionalization. They excel in drug delivery, tissue engineering, and stimuli‐responsive therapies, enabling targeted and controlled treatments. With roles in cancer therapy and diagnostics, their clinical translation requires addressing challenges in ...
Miguel Manzano, María Vallet‐Regí
wiley +1 more source
Meningococcal conjugate vaccines: optimizing global impact
Andrew Terranella1,2, Amanda Cohn2, Thomas Clark2 1Epidemic Intelligence Service, Division of Applied Sciences, Scientific Education and Professional Development Program Office, 2Meningitis and Vaccine Preventable Diseases Branch, National Center for ...
Terranella A, Cohn A, Clark T
doaj
Inspired by viral entry mechanisms, the FUSION assay enables autonomous detection of respiratory viruses via membrane fusion–triggered CRISPR‐Cas13a activation. VEACON selectively fuses with fusion‐competent viruses, triggering fluorescence within confined vesicles.
Jae Chul Park +15 more
wiley +1 more source

